Sleeve gastrectomy with transit bipartition: a review of the literature.

INTRODUCTION: Obesity has been identified by the World Health Organization (WHO) as a significant global medical, social, and public health issue. Surgery is the most important therapeutic option for severe morbid obesity and metabolic diseases linked to obesity. Sleeve gastrectomy-transit bipartition (SG-TB) and the single anastomosis sleeve ileal (SASI) bypass, a more simplified variation of SG-TB, have recently become popular methods for treating these conditions. The clinical investigations of SG-TB and SASI bypass are included in this review. In order to find papers published up until December 2022, the Pubmed database was searched.

AREAS COVERED: We comprehensively review the most recent research on the use of SG-TB and SASI bypass in clinical practice, including the surgical technique, weight loss, comorbidity remission, post-operative complications, post-operative nutritional status, and the mechanism of operation.

EXPERT OPINION: Studies on the SG-TB and SASI bypass have shown positive short-term outcomes. The weight loss and improvement of comorbid conditions with SG-TB and SASI bypass have shown promising results. In comparison to other operations, it has also been demonstrated that there is a relatively low incidence of adverse effects. However, more research is necessary to determine its long-term effectiveness and to address several intriguing issues.